# US 2002/0119126 A1 · Differentiation of adipose stromal cells into osteoblasts and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0119126 A1
- Document ID: US20020119126A1
- Status: Published application
- Kind: A1
- Application number: 10/061,214
- Filed: 2002-03-14
- Published: 2002-08-29
- Earliest claimed: 1997-12-02
- Assignees: Zen Bio, Inc.
- Inventors: Yuan-di C. Halvorsen
- Web page: https://patentgrep.com/patent/US20020119126A1

## CPC

- C12N 5/0654: {Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth}
- A61K 35/32: Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61F 2/28: Bones
- A61F 2002/2817: {Bone stimulation by chemical reactions or by osteogenic or biological products for enhancing ossification, e.g. by bone morphogenetic or morphogenic proteins [BMP] or by transforming growth factors [TGF]}
- A61F 2002/2835: {Bone graft implants for filling a bony defect or an endoprosthesis cavity, e.g. by synthetic material or biological material}
- A61F 2002/30677: {Means for introducing or releasing pharmaceutical products, e.g. antibiotics, into the body}
- A61F 2002/4648: {Means for culturing bone graft}
- A61F 2310/00293: containing a phosphorus-containing compound, e.g. apatite
- A61F 2310/00365: Proteins; Polypeptides; Degradation products thereof
- A61F 2310/00383: Gelatin
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2500/34: Sugars
- C12N 2500/38: Vitamins
- C12N 2500/42: Organic phosphate, e.g. beta glycerophosphate
- C12N 2501/155: Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
- C12N 2502/1305: Adipocytes
- C12N 2506/13: from connective tissue cells, from mesenchymal cells
- C12N 2506/1384: from adipose-derived stem cells [ADSC], from adipose stromal stem cells
- C12N 2510/00: Genetically modified cells
- C12N 2533/14: Ceramic
- C12N 2533/54: Collagen; Gelatin
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61F: FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS (dental prosthetics A61C)

## Abstract

The invention provides methods and compositions for differentiating stromal cells from adipose tissue into cells having osteoblastic properties, and methods for improving a subject's bone structure. The methods comprise culturing stromal cells from adipose tissue in β-glycerophosphate and ascorbic acid and/or ascorbate-2-phosphate for a time sufficient to allow differentiation of said cells into osteoblasts. Such methods and compositions are useful in the production of osteoblasts for autologous transplantation into bone at a surgical site or injury. The compositions comprise adipose stromal cells, a medium capable of supporting the growth of fibroblasts and amounts of β-(glycerophosphate and ascorbic acid and/or ascorbic-2 phosphate sufficient to induce the differentiation of said stromal cells into osteoblasts. The invention further provides methods of identifying compounds that affect osteoblast differentiation. Such compounds are useful in the study of bone development and in the treatment of bone disorders, including bone fractures and osteoporosis.

## Claims

### Claim 1

1) A method of differentiating adipose stromal cells into osteoblasts, comprising: culturing said cells in a composition comprising a medium capable of supporting the growth of fibroblasts and differentiation inducing amounts of β-glycerophosphate and ascorbic acid and/or ascorbic-2 phosphate.

### Claim 2 (depends on 1)

2) The method of claim 1, wherein said amounts are about 2-20 mM β-glycerophosphate and about 20-75 μM ascorbic acid and/or ascorbic-2 phosphate.

### Claim 3 (depends on 2)

3) The method of claim 2 wherein said amounts are about 5-15 μM β-glycerophosphate and about 40-60 μM ascorbic acid and/or ascorbic-2 phosphate.

### Claim 4 (depends on 3)

4) The method of claim 3, wherein said amounts are about 10 mM β-glycerophosphate and about 50 μM ascorbic acid and/or ascorbic-2 phosphate.

### Claim 5 (depends on 1)

5) The method of claim 1, wherein said medium is selected from the group consisting of: DMEM, αMEM and BME.

### Claim 6 (depends on 1)

6) The method of claim 1, wherein said medium further comprises about 5-20% fetal calf serum.

### Claim 7 (depends on 1)

7) The method of claim 1, wherein said medium further comprises one or more bone morphogenetic proteins.

### Claim 8 (depends on 1)

8) The method of claim 1 wherein said cells are mammalian.

### Claim 9 (depends on 8)

9) The method of claim 8 wherein said cells are human.

### Claim 10

10) A method of identifying compounds that affect osteoblast differentiation, comprising:
a) culturing adipose stromal cells in the presence and absence of a compound to be tested for effect on osteoblast differentiation in a composition which comprises a medium capable of supporting the growth of fibroblasts and differentiation inducing amounts of β-glycerophosphate and ascorbic acid and/or ascorbic-2 phosphate; and
b) comparing osteoblast differentiation in said cells cultured in the presence of said compound to that of said cells cultured in the absence of said compound.

### Claim 11 (depends on 10)

11) The method of claim 10, wherein said amounts are about 2-20 mM β-glycerophosphate and about 20-75 μM ascorbic acid and/or ascorbic-2 phosphate.

### Claim 12 (depends on 11)

12) The method of claim 11, wherein said amounts are about 5-15 mM β-glycerophosphate and about 40-60 μM ascorbic acid and/or ascorbic-2 phosphate.

### Claim 13 (depends on 12)

13) The method of claim 12, wherein said amounts are about 10 mM β-glycerophosphate and about 50 μM ascorbic acid and/or ascorbic-2 phosphate.

### Claim 14

14) A method of improving a subject's bone structure, comprising:
a) culturing adipose stromal cells in a composition which comprises a medium capable of supporting the growth of fibroblasts and differentiation inducing amounts of β-glycerophosphate and ascorbic acid and/or ascorbic-2 phosphate; and
b) introducing said osteoblasts into a surgery or fracture site of said subject.

### Claim 15 (depends on 14)

15) The method of claim 14, wherein said amounts are about 2-20 mM β-glycerophosphate and about 20-75 μM ascorbic acid and/or ascorbic-2 phosphate.

### Claim 16 (depends on 15)

16) The method of claim 15, wherein said amounts are about 5-15 mM β-glycerophosphate and about 40-60 μM ascorbic acid and/or ascorbic-2 phosphate.

### Claim 17 (depends on 16)

17) The method of claim 16, wherein said amounts are about 10 mM β-glycerophosphate and about 50 μM ascorbic acid and/or ascorbic-2 phosphate.

### Claim 18 (depends on 14)

18) The method of claim 14, wherein said adipose stromal cells are isolated from said subject.

### Claim 19 (depends on 14)

19) The method of claim 14, wherein said medium is selected from the group consisting of: DMEM, αMEM and BME.

### Claim 20 (depends on 14)

20) The method of claim 14, wherein said medium further comprises about 5-20% fetal calf serum.

### Claim 21 (depends on 14)

21) The method of claim 14, wherein said medium further comprises one or more bone morphogenetic proteins.

### Claim 22 (depends on 14)

22) The method of claim 14, wherein said subject is mammalian.

### Claim 23 (depends on 22)

23) The method of claim 22, wherein said subject is human.

### Claim 24 (depends on 14)

24) The method of claim 14, wherein said osteoblasts are introduced in admixture with a composition useful in the repair of bone wounds, bone defects and/or bone disorders.

### Claim 25 (depends on 14)

25) The method of claim 14, wherein a nucleotide sequence of interest is introduced into said adipose stromal cells or said osteoblasts.

### Claim 26

26) A composition comprising adipose stromal cells, a medium capable of supporting the growth of fibroblasts and amounts of β-glycerophosphate and ascorbic acid and/or ascorbic-2 phosphate sufficient to induce the differentiation of said stromal cells into osteoblasts.

### Claim 27 (depends on 26)

27) The composition of claim 26, wherein said amounts are about 2-20 mM β-glycerophosphate and about 20-75 μM ascorbic acid and/or ascorbic-2 phosphate.

### Claim 28 (depends on 27)

28) The composition of claim 27, wherein said amounts are about 5-15 mM β-glycerophosphate and about 40-60 μM ascorbic acid and/or ascorbic-2 phosphate.

### Claim 29 (depends on 28)

29) The composition of claim 28, wherein said amounts are about 10 mM β-glycerophosphate and about 50 μM ascorbic acid and/or ascorbic-2 phosphate.

### Claim 30 (depends on 26)

30) The composition of claim 26, wherein said stromal cells are human.
